Please select the option that best describes you:
Under what circumstances would you consider obinutuzumab instead of rituximab when treating primary membranous nephropathy?
Answer from: at Academic Institution
Obinutuzumab is a Type II fully humanized glycoengineered anti-CD20 monoclonal antibody with marked B-Cell depletion along with greater antibody dependent cytotoxicity when compared to Rituximab.Currently, its use in 'primary' membranous nephropathy is limited to only refractory cases wherein Rituxi...
Sign in or Register to read more